New research argues that the oral alternative to injected semaglutide could also help improve the symptoms of diabetes and ...

Ron Grunstein, MD, PhD, head of sleep and circadian research, Woolcock Institute of Medical Research, shares findings from a ...

The US FDA has approved once-daily Onyda XR as the first liquid, nonstimulant treatment for attention-deficit/hyperactivity disorder (ADHD).

A new study in mice suggests that blocking the GLP-1 receptor may help defend against colorectal cancer, begging the question ...

Narcolepsy type 1 is a rare, chronic central nervous system disorder defined by a loss of orexin neurons, with common ...

Zealand Pharma’s GLP-1/GLP-2 receptor dual agonist may have only managed at best an average 4.3% reduction in weight loss ...

C HICAGO -- The investigational CD40 agonist mitazalimab and modified FOLFIRINOX demonstrated encouraging activity in ...

Analyst Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Harmony Biosciences Holdings (HRMY – Research Report) and ...

The researchers found that 358,075 of 1.7 million individuals were dispensed antidepressants, and 8495 of the 24,783 dispensed a GLP-1 receptor agonist were also dispensed an antidepressant in ...

In the majority of IVF cycles, whether using an agonist or an antagonist protocol, the trigger used is human chorionic gonadotropin (hCG), which shares a common subunit with LH and thus acts as a ...

Patients who received CT-388 had an average placebo-adjusted weight loss of 18.8%. CT-388 is well tolerated with only mild to ...

Individuals taking glucagon-like peptide (GLP)-1 receptor agonists have a greater risk for subsequently being dispensed antidepressants.